Mepolizumab reduced COPD exacerbations in patients with eosinophilic inflammation, highlighting the potential of ...
The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a ...
Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...
Hospitalizations for bronchiectasis exacerbations are associated with poorer in-hospital outcomes than those for chronic obstructive pulmonary disease or asthma exacerbations.
Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...
Background In real-world chronic obstructive pulmonary disease (COPD) care, poor adherence often leads to treatment ...
In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...
Early termination of the 6-minute walk test may be a practical and prognostic marker for severe adverse events in patients with COPD.
London: GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
Non-cystic fibrosis bronchiectasis (NCFB) is a heterogeneous disease characterised by a ‘vicious vortex’ of ...
Kolkata: A surge in pneumonia and COPD patients has left several private hospitals close to full occupancy, leading to a ...
GSK’s Nucala receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease: London, UK Monday, December 15, 2025, 16:00 Hrs [IST] GSK plc announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback